AI Article Synopsis
- The study focuses on patients with psoriatic arthritis (PsA) to assess axial joint involvement using MRI and the impact of 24-week adalimumab treatment.
- It involved 37 PsA patients, revealing high rates of spondylitis (91%) and varying degrees of sacroiliitis, with the thoracic spine being the most affected area.
- The treatment with adalimumab significantly improved both the number of spondylitis sites and the severity of sacroiliitis after 24 weeks.
Article Abstract
Objectives: PsA is characterized by enthesitis, synovitis and osseous involvement in the peripheral and axial joints. Few studies have examined axial involvement in PsA using imaging techniques. Here we examined axial involvement in PsA patients using MRI. In addition, we determined the efficacy of 24 week adalimumab treatment in improving the MRI findings of spondylitis and sacroiliitis.
Methods: This was a prospective, open-label, single-arm study in patients with PsA. Adalimumab was administered to patients for a total of 24 weeks. MRI examinations were conducted at baseline and at week 24 of adalimumab treatment.
Results: Thirty-seven patients with PsA were included in this study. Spondylitis was observed in at least one site of the positive scan in 91% (n = 31) of patients with PsA. The number of arthritic sites in the cervical, thoracic and lumbar regions of the spine was 48, 67 and 53, respectively. All patients had MRI-determined sacroiliitis of grade ≥1 severity while 28 patients (82%) had grade ≥2 sacroiliitis in at least one sacroiliac region. Sacroiliac arthritis was statistically more severe on the right side than on the left side (P < 0.05). In 34 patients with PsA, the thoracic spine was the most common site of spondylitis. In addition, 24 week adalimumab treatment led to an improvement in the mean number of spondylitis sites and the mean grade of sacroiliitis.
Conclusion: Treatment with adalimumab for 24 weeks resulted in improvement in spondylitis and sacroiliitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/keaa829 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rapid and Deep Prostate-Specific Antigen Decline is a Prognostic Marker in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Multi-Intuitional Analysis.
Prostate
December 2024
Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Background: Prostate-specific antigen (PSA) kinetics has been investigated as a prognostic marker in post hoc analyses of clinical trials. This study validated the prognostic value of rapid and deep PSA decline in metastatic hormone-sensitive prostate cancer (mHSPC) using real-world data.
Methods: In total, 1296 patients with mHSPC were retrospectively reviewed.
Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases.
J Pharm Technol
December 2024
Rheumatology Department, Hospital de Sagunto, Port de Sagunt, Spain.
Provide real-world data on switching from adalimumab biosimilar MSB11022 to GP2017 related to persistence, adherence, and safety in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Retrospective cohort study that used registries and medical records from a single hospital (June 2022 to April 2024). Adult patients with RA, PsA, and axSpA treated with adalimumab biosimilar MSB11022 who switched to biosimilar GP2017 were identified and followed up until April 2024, or disenrollment.
View Article and Find Full Text PDFOutcomes of Systematic Transrectal Ultrasound-Guided Prostate Biopsy Performed by a Surgical Care Practitioner and Implications for Resource-Poor Countries.
Cureus
November 2024
Urology, Peterborough City Hospital, Peterborough, GBR.
Introduction Prostate cancer remains the most prevalent cancer among men and continues to present a significant public health challenge globally. The disease's growing prevalence has heightened the demand for skilled professionals capable of obtaining histological samples for accurate diagnosis, as tissue biopsy remains the cornerstone for diagnosing prostate cancer. Surgical care practitioners have become integral to the surgical team, and their roles have expanded to include performing biopsies.
View Article and Find Full Text PDFPSA testing in primary care: is it time to change our practice?
BMC Prim Care
December 2024
Department of Urology, Erasmus Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Background: Historical prostate-specific antigen (PSA)-based screening studies reduced prostate cancer-related deaths but also led to overdiagnosis/overtreatment. Since then, opportunistic PSA testing has increased, and late-stage diagnoses and prostate-cancer related deaths are rising.
Objectives: To review current trends regarding PSA testing in primary care and propose a collaborative approach to improve early prostate cancer detection.
'Pacing System Analyzers to guide Conduction System Pacing implantation procedures: A comparison study of intracardiac and surface signals with an Electrophysiological Recording System'.
Heart Rhythm
December 2024
Electrophysiology Unit. Cardiovascular Division. Hospital del Mar. Passeig Maritim de la Barceloneta. Barcelona. Spain; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Background: Left bundle branch area pacing (LBBAP) needs confirmation of left conduction system capture assessed by testing of different electrical parameters. Guidelines recommend the use of an electrophysiological recording-system (EP-RS) to guide conduction system pacing (CSP) procedures. However, some experienced centers perform LBBAP procedures without an EP-RS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!